------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Molecular Profiling Institute Secures $7.5 million in Series B
Funding; AmeriPath, Affymetrix, and Gen-Probe Provide Funding to
Accelerate the Introduction of New Genetic-Based Prognostics to
Cancer Patients

PHOENIX ARIZONA Oct. 28, 2005 The Molecular Profiling Institute,
Inc. (Molecular Profiling) today announced that it has secured $7.5
million in capital through a Series B financing from three key
investors: AmeriPath, Affymetrix and Gen-Probe Incorporated.
Molecular Profiling is a leading specialty reference laboratory that
utilizes proprietary genomic analysis methods to guide treatment
decisions for cancer patients.

"Our series B funding will accelerate the introduction of our new
genetic-based profiling to oncology patients," said Dr. Robert J.
Penny, Molecular Profiling President and CEO.

The funding will be utilized to launch additional molecular tests in
the areas of breast cancer, prostate cancer, and lymphoma and to
develop additional assays through collaborations in clinical trials
that indicate populations of patients who may best respond to
targeted cancer therapies. Among the testing offered, Molecular
Profiling has an exclusive license to provide the MammaPrint(R) 70
gene breast cancer prognostic in the United States and also provides
tissue banking and analysis services for a number of pharmaceutical
organizations.

Molecular Profiling's advanced tests are provided principally
through their partner AmeriPath, one of the leading anatomic
pathology laboratory companies in the United States. "Following
AmeriPath's planned acquisition of Specialty Laboratories, an
enhanced role in Molecular Profiling enables us to better provide
the latest and best testing for cancer patients to a wider patient
base," said Keith Laughman, President for Esoteric Services at
AmeriPath. "Molecular Profiling gives us unique access to a top
genetic testing laboratory and a pipeline to unique proprietary
testing, which is important to our pathologists as we deliver
premier healthcare to the communities and the patients that we
serve."

Robert Lipshutz, Ph.D., Senior Vice President, Emerging Markets and
Molecular Diagnostics at Affymetrix stated that "We are pleased to
be working with Molecular Profiling to accelerate scientific
breakthroughs that will help improve patient care." Affymetrix'
GeneChip technology enables researchers to identify and measure
genes that are similarly expressed among a group of people who share
the same disease.

Gen-Probe, which manufactures a broad portfolio of diagnostic and
blood screening products to detect a variety of diseases, has also
established a collaboration with Molecular Profiling to validate and
commercialize certain of its investigational assays. The first will
be the investigational PCA3 test, which is intended as an aid in the
diagnosis of prostate cancer. Henry L. Nordhoff, Chairman, President
and CEO of Gen-Probe stated that "Molecular Profiling has the
capability to facilitate our product validation and market entry."

Molecular Profiling was founded as the conduit for the commercial
application of the Translational Genomics Research Institute's
(TGen) research projects and the International Genomics Consortium's
(IGC) tissue banking and analysis capabilities.

About the Molecular Profiling Institute Inc. - Molecular Profiling
is a CLIA-certified specialty reference laboratory that helps cancer
patients worldwide by applying the discoveries of the Human Genome
Project to personalized medicine. Molecular Profiling provides
cutting-edge testing facilities, products, and resources for genomic
and proteomic profiling and treatment of cancers and pharmaceutical
services to identify populations that may respond to targeted
therapies. Molecular Profiling has strategic relationships with
AmeriPath Inc., Affymetrix Inc., Gen-Probe Inc., IBM, the
International Genomics Consortium (IGC), and the Translational
Genomics Research Institute (TGen). For more information, please see
www.molecularprofiling.com.

About Affymetrix - Affymetrix scientists invented the world's first
microarray in 1989 and began selling the first commercial microarray
in 1994. Since then, Affymetrix GeneChip(R) technology has become
the industry standard in molecular biology research. Affymetrix
technology is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,300 systems have
been shipped around the world and more than 3,000 peer-reviewed
papers have been published using the technology. Affymetrix'
patented photolithographic manufacturing process provides the most
information capacity available today on an array, enabling
researchers to use a whole-genome approach to analyze the
relationship between genetics and health. Headquartered in Santa
Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in
addition to manufacturing facilities in Sacramento, Calif. and
Bedford, Mass. The company has about 1000 employees worldwide. For
more information, please see www.affymetrix.com.

About AmeriPath Inc. - AmeriPath is one of the leading anatomic
pathology laboratory companies in the United States. AmeriPath
offers a broad range of testing and information services used by
physicians in the detection, diagnosis, evaluation and treatment of
cancer and other diseases and medical conditions. The company's
extensive diagnostics infrastructure includes over 400 pathologists
and doctorate-level scientists providing services in over 20 states
utilizing 40 independent pathology laboratories, more than 200
hospitals, and their Centers of Excellence. For more information,
please see www.ameripath.com.

About Gen-Probe - Gen-Probe Incorporated is a global leader in the
development, manufacture and marketing of rapid, accurate and cost-
effective nucleic acid tests (NATs) used to diagnose human diseases
and screen donated human blood. Gen-Probe markets a broad portfolio
of products that use the Company's patented technologies to detect
infectious microorganisms, including those causing sexually
transmitted diseases, tuberculosis, strep throat, pneumonia and
fungal infections. The Company also developed and manufactures the
only FDA-approved blood-screening assay for the simultaneous
detection of HIV-1 and HCV, which is marketed by Chiron Corporation.
In addition, Gen-Probe's TIGRIS instrument is the only fully
automated, high-throughput NAT system for diagnostics and blood
screening. For more information, please see www.gen-probe.com.

About the International Genomics Consortium (IGC) - IGC is a non-
profit medical research foundation established to serve common,
unmet needs including: the standardization of the collection of
properly consented tissues of interest, the molecular
characterization of these tissues, and standardization in the
representation of these results. For more information, please see
www.intgen.org.

About the Translational Genomics Research Institute (TGen) - TGen's
mission is to make and translate genomic discoveries into advances
in human health. "Translational research" is a relatively new field
employing innovative advances, such as genome-wide array technology,
and the burgeoning field of computational biology, to provide the
data and tools necessary to identify the genes that play a role in
hereditary susceptibility to disease. For more information, please
see www.tgen.org.

http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech